Trodelvy
Active Ingredient(s): Sacituzumab Govitecan-hziyFDA Approved: * April 22, 2020
Pharm Company: * IMMUNOMEDICS INC
Category: Cancer
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.[5][7][8][9] The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain.[8&am... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.